A U.S. dollar note and pills in an illustration photo. Dado Ruvic/Reuters
The U.S. tariff policy and its unmatched pharmaceutical market are pulling European drugmakers to invest more heavily, from new manufacturing plants to U.S. stock listings and discount pricing deals.
Since early 2025, European drugmakers have stepped up their U.S. presence. In the most recent move, UK pharmaceutical giant AstraZeneca announced on Sept. 29 a direct listing on the New York Stock Exchange, just months after pledging $50 billion of U.S. investment by 2030.
